The city of Glendale, California, currently has 2 active clinical trials seeking participants for Atopic Dermatitis research studies.
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
Recruiting
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2024
Locations: Up0110 101, Glendale, California
Conditions: Atopic Dermatitis
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single (SAD) and multiple doses (MAD) of NM26-2198.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/09/2024
Locations: California Clinical Trials Medical Group (CCTMG) managed by Parexel, Glendale, California
Conditions: Atopic Dermatitis